Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 55

Results For "GE"

6976 News Found

Caplin Steriles gets USFDA approval for Rocuronium Bromide Injection
Drug Approval | March 04, 2023

Caplin Steriles gets USFDA approval for Rocuronium Bromide Injection

Rocuronium Bromide Injection is a neuromuscular blocking agent


Jan Aushadhi Train flagged off by Mandaviya and Vaishnaw in New Delhi
News | March 04, 2023

Jan Aushadhi Train flagged off by Mandaviya and Vaishnaw in New Delhi

Jan Aushadhi highlights achievements of women of the country at 34 locations by felicitating all women stakeholders under the scheme


ProBioGen’s growth strategy continues successfully
News | March 03, 2023

ProBioGen’s growth strategy continues successfully

Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team


Dr. Reddy's Laboratories to acquire Mayne Pharma’s U.S. generic prescription product portfolio
News | March 01, 2023

Dr. Reddy's Laboratories to acquire Mayne Pharma’s U.S. generic prescription product portfolio

The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.


NATCO launches generic Pomalidomide Capsules in Canada
News | March 01, 2023

NATCO launches generic Pomalidomide Capsules in Canada

Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules


Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg
Drug Approval | February 27, 2023

Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg

Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.


EMA recommends refusal of the marketing authorization for Lagevrio
News | February 25, 2023

EMA recommends refusal of the marketing authorization for Lagevrio

Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.


SERDA therapeutics submits IND for wound debridement agent
Drug Approval | February 24, 2023

SERDA therapeutics submits IND for wound debridement agent

Clinical studies are expected to start in Q2 2023.